The American Journal of Managed Care

5 Things to Know if Retatrutide Is Classified as a Biologic

"We believe retatrutide is a biologic application," Eli Lilly’s CEO Dave Ricks, MBA, told analysts on the company's second-quarter earnings call in August. The outcome will shape how long retatrutide ...

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Châtillon, Franc DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut ...
Nasdaq

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India & REYKJAVIK, Iceland--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its ...
PR Newswire

Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Di…

About Pierre Fabre Pharmaceuticals and Laboratoires Pierre Fabre The mission of PFP is to deliver breakthrough therapies in ...
Business Wire

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the ...

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ...
Seeking Alpha

Alvotech and Dr. Reddy’s biosimilar for Amgen's Prolia under FDA review

Dr. Reddy’s Laboratories (NYSE:RDY) and Alvotech (NASDAQ:ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03, a biosimilar targeting Amgen's (NASDAQ:AMGN ...
JD Supra

Biological Products Regulation Part 5: Preparing for the FDA’s Pre-License Inspection

In the fifth part of our FDA: Drug & Device Team’s series on biological products regulation, we discuss key considerations for biologics license applications (BLAs) and the Food and Drug ...
India

USFDA accepts Biological License Application from Sun Pharma

Mumbai, May 24 (IANS) Drug major Sun Pharmaceutical Industries Ltd on Wednesday said the US Food and Drug Administration (USFDA) has accepted its Biological License Application (BLA) for tildrakizumab ...
MarketScreener

Alvotech S.A. Receives FDA Approval For Supplement To Biologics License Application For AVT02

Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved a supplement to the Biologics License Application (BLA) for AVT02 (adalimumab-ryvk), marketed in the U.S. as SIMLANDI®, ...
Nasdaq

Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech (NASDAQ: ALVO), a global biotech ...
MarketScreener

DBV Technologies Submits Biologics License Application To U.S. FDA For The VIASKIN® Peanut Patch In Children Aged 4-7 Years

DBV Technologies announced that the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the VIASKIN® Peanut Patch in children with peanut ...